CSF2 and pulmonary alveolar proteinosis: A clinical trial named “clinical observation of subcutaneous injection of low-dose rhGM–CSF on treatment of PAP” (ID number is NCT01983657) was registered to further verify the efficacy of low-dose recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) for PAP.